VASO VASO Corp
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 839087 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.2%
TTM net income YoY-5.0%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-5.9%
Net income 3-yr CAGR-40.6%
Margins
Gross margin68.2%
Operating margin-3.7%
Net margin3.6%
FCF margin—
EBITDA margin-2.3%
Returns
ROE8.3%
ROA2.9%
ROIC (approx.)—
Asset turnover0.82x
Leverage & solvency
Liabilities / assets62.8%
Debt / equity0.00x
Current ratio2.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.77x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $89.10M | $86.77M |
| Cost of revenue | $34.42M | $34.72M |
| Gross profit | $54.67M | $52.05M |
| R&D expense | $728,000 | $851,000 |
| SG&A expense | $52.20M | $48.98M |
| Operating income | -$2.89M | $285,000 |
| Interest expense | $25,000 | $4,000 |
| Pretax income | -$1.31M | $1.28M |
| Income tax | -$2.88M | $326,000 |
| Net income | $1.57M | $951,000 |
| EBITDA | -$2.03M | $1.11M |
| EPS (basic) | 0.01 | 0.01 |
| EPS (diluted) | 0.01 | 0.01 |
| Weighted avg. shares (diluted) | 176.00M | 175.59M |
| Balance sheet | ||
| Cash & equivalents | $34.08M | $26.27M |
| Receivables | — | $916,000 |
| Inventory | $833,000 | $911,000 |
| Current assets | $58.56M | $51.19M |
| PP&E, net | $121,000 | $1.54M |
| Goodwill | $1.23M | $1.18M |
| Intangibles | $1.25M | $1.61M |
| Total assets | $89.32M | $82.94M |
| Current liabilities | $36.85M | $34.72M |
| Total liabilities | $59.89M | $55.24M |
| Shareholders' equity | $29.43M | $27.70M |
| Shares outstanding | 175.95M | 175.70M |
| Cash flow statement | ||
| Operating cash flow | $9.27M | $3.28M |
| Investing cash flow | -$725,000 | $11.73M |
| Financing cash flow | $248,000 | -$89,000 |
| Depreciation & amortization | $858,000 | $824,000 |
| Stock-based compensation | $33,000 | $54,000 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.